

February 18, 2022

From Eric's Desk

As of this morning, I have on the job for 14 days. I have had a whirlwind initiation. I have met more people than one can fathom despite my many introductions by Zoom over the past three months. I am overjoyed to be back in New Haven after over 30 years. And if early impressions are accurate, I will have a long and happy tenure at Yale Cancer Center and Smilow Cancer Hospital.

One of our early initiatives, as announced in DirectConnect today, is a reinvestment in our hematology/oncology training program led by Alfred Lee, MD, PhD. With an infusion of faculty commitment and financial support, Dr. Lee will develop one of the foremost programs in the country. Compared to fellowship programs at other major centers, our approach will be more individualized with the goal of supporting every fellow to pursue their personal objectives for training and beyond. Hematology/oncology is the first program we will tackle, but our plan is to support all training programs throughout the cancer center over the years ahead.

A brief synopsis of my experience to date:

TOP 5

5. The New Haven restaurant scene is great and getting even better.
4. Everyone at Yale has been generous, accepting, welcoming, and frankly a joy.
3. There is outstanding clinical care.
2. The science is truly stellar.
1. There is phenomenal team spirit that will facilitate clinical expansion, team science, and excellence across all areas.

BOTTOM 5

5. I am convinced that the walls in my office are painted mint green. I look incredibly ill in a sea of light green.
4. I keep getting lost. The halls and buildings are designed to make me turn in the wrong direction every time I leave my office.
3. But at the same time, everything looks the same as it did in 1987 -- that is, a few updates just might be needed!
2. Does any city have traffic lights that stay red for so long?
1. Big universities are bureaucratic and can require endless approvals for anything new, but fortunately, this just requires a creative approach and a strong will.

from the desk of

Eric P. Winer, MD


Director, Yale Cancer Center
Physician-in-Chief,
Smilow Cancer Hospital

Yale
NewHaven
Health
Smilow Cancer
Hospital

Yale **CANCER**
CENTER
A Comprehensive Cancer Center Designated
by the National Cancer Institute

News Center

Can Cancer Patients Get Approved COVID Therapies?



[Read More](#)

YSM, YNH, YCC, and Smilow are truly incredibly. I am honored and humbled to be here working with all of you in pursuit of a very noble mission.

Eric

Announcements

Roy S. Herbst, MD, PhD, Appointed Deputy Director for Clinical Affairs and Assistant Dean for Translational Research

I am very pleased to announce the appointment of Roy S. Herbst, MD, PhD, as the inaugural Deputy Director for Clinical Affairs at Yale Cancer Center and Smilow Cancer Hospital. This new appointment is effective immediately. As Deputy Director for Clinical Affairs, Dr. Herbst and I will work closely together on all aspects of our clinical programs to ensure our future success. Given Dr. Herbst's longstanding commitment to the integration of clinical, translational, and basic research programs, he is uniquely qualified for this position.



In addition, Dr. Herbst has been appointed by Dean Nancy Brown, MD, as Assistant Dean for Translational Research at Yale School of Medicine. In his new role at YSM, Dr. Herbst will focus initially on two major initiatives. First, he will work to promote transdisciplinary interactions among faculty within YSM and across the university with partners in industry to accelerate discovery and the translation for patients of new diagnostics and therapies. Second, he will develop and launch a Master of Science in Clinical Investigation program to train fellows and junior faculty in hypothesis-driven, mechanistic human research, including first-in-human studies.


Investment in Hematology/Oncology Fellowship Program Announced

Yale Cancer Center has further invested in our Hematology/Oncology Fellowship Program with a new \$1.5 million commitment to the program. This will ensure an even steeper trajectory for the Fellowship Program with new programmatic development and individual support for our fellows to pursue educational opportunities, research projects, and launch their careers at Yale Cancer Center.

Yale Cancer Center's Hematology/Oncology Fellowship Program has been a keystone of our education and training mission since its inception in 1964 training leaders in research, clinical care, industry, and every sector of hematology and oncology. Jill Lacy, MD, Professor of Medicine, led the program for over two decades with vision, creativity, and commitment, providing an outstanding educational and research experience for our fellows.


In 2020, Alfred I. Lee, MD, PhD, was appointed Director of the program. Dr.

Yale Cancer Center Study Validates New Therapy for Aggressive Bladder Cancer



[Read More](#)

Cary Gross, MD, in Honor of Cancer Prevention Awareness Month



[Read More](#)

New Drug Combination Shown Effective for Patients With Advanced Ovarian Cancer



[Read More](#)

Seeing Is Believing - Mapping How Cell Types and Tissues Develop

Lee's passion and dedication to the growth, mentorship, and prospects for our trainees has propelled our program even further to provide new opportunities for basic, translational, population, and clinical research.

Dr. Lee will work closely with Roy S. Herbst, MD, PhD, Deputy Director for Clinical Affairs and Chief of Medical Oncology, Stephanie Halene, MD, PhD, Chief of Hematology, and the Associate Directors of the Fellowship Program, to plan and implement new resources over the coming years, including expanding the core faculty mentors to include basic and translational scientists at Yale Cancer Center, retaining fellows post-fellowship, and providing fellows funding to support additional academic goals at Yale. [Link to full release](#)

Dr. David J. Carlson Appointed Vice Chair of Therapeutic Radiology and Director of Medical Physics

The Department of Therapeutic Radiology is pleased to announce that David J. Carlson, PhD, DABR, FAAPM, will join the Department of Therapeutic Radiology and the Smilow Cancer Hospital Radiation Oncology team in April as Vice Chair and Director of Medical Physics. Dr. Carlson comes to us from the University of Pennsylvania, where he is currently an Associate Professor and the Director of Physics Operations in the Department of Radiation Oncology.



Dr. Carlson is a Middlebury College graduate who received his doctoral degree in Medical Physics from Purdue University in 2006 and completed his residency in Radiation Oncology Physics at Stanford University in 2008. After his residency, he joined the Yale faculty and medical physics team where he served for just over a decade. Dr. Carlson's clinical and research interests include the clinical implementation of novel technology and translational multidisciplinary collaborations with physicians and biologists. The goals of his research are to improve radiation therapy outcomes for patients with cancer by developing accurate models of treatment response and to advance our understanding of the underlying biophysical mechanisms that govern radiation response. Dr. Carlson currently serves as Senior Editor for the *International Journal of Radiation Oncology, Biology, and Physics*, is a Fellow and past member of the Board of Directors of the American Association of Physicists in Medicine (AAPM), and is Chair of the Science Education and Program Development committee of the American Society for Radiation Oncology (ASTRO).

Cancer Immunology Leadership

I am pleased to announce **Marcus Bosenberg, MD, PhD**, Professor of Dermatology, Pathology, and Immunobiology, and Director of the Yale Center for Immuno-Oncology, has joined Carla Rothlin, PhD, and Mario Sznol, MD, as Co-Leaders of the Cancer



Examples of spatial mapping of histone modifications


[Read More](#)

Honoring the Interim: Thank You Note



[Read More](#)

'Decision Switch' Discovered in Mutations Linked to Common Brain Tumor



[Read More](#)

Follow us!

facebook



Immunology Research Program. Dr. Bosenberg's leadership of the Center for Immuno-Oncology and expertise in this area will provide the synergy needed between our Cancer Immunology Program and the Center to coordinate research efforts in this area throughout Yale Cancer Center and Yale School of Medicine. His own laboratory research has developed several widely utilized mouse models to study how melanoma forms and progresses, to test new melanoma therapies, and to determine how the immune system can be stimulated to fight melanoma. The joint leadership between Dr. Bosenberg, Dr. Rothlin, and Dr. Sznol will continue Yale Cancer Center's momentum and high-impact translation in Cancer Immunology and Immuno-Oncology.



Lieping Chen, MD, PhD, United Technologies Corporation Professor in Cancer Research and Professor of Immunobiology, Dermatology and Medicine (Medical Oncology), has stepped down from his role as Co-Leader of the Cancer Immunology Research Program, and joins the Translational Research Office at Yale Cancer Center as Special Advisor for Immunotherapy, Office of Translational Research. Dr. Chen will work along with Roy S. Herbst, MD, PhD, Associate Cancer Center Director for Translational Research. Dr. Chen's research and subsequent discovery of the PD-1/PD-L1 pathway for cancer immunotherapy was cited as the #1 breakthrough of the year by *Science* magazine in 2013. He is a member of the National Academy of Sciences and a Fellow of the American Association for Cancer Research and the Society for Immunotherapy of Cancer.



Annual Award Winners Celebrated at Virtual Conclave

Yale Cancer Center's annual Conclave was celebrated virtually on Tuesday, February 15 to honor the scientific and clinical accomplishments of 2021, and to highlight the devotion of our physicians, scientists, nurses, and staff through another challenging year.

Yale Cancer Center
Lifetime Achievement Award



Meet Rachel Greenup, MD, MPH, surgical oncologist and Chief of Breast Surgery at Smilow Cancer Hospital. One of Dr. Greenup's patients recently shared: "Dr. Greenup was very clear in her explanation of my condition, treatment and prognosis. She explained everything with care and compassion. She was reassuring and comforting. I was introduced to the other people in the room, PA, Fellow, Nurse- everyone was reassuring and helpful. The entire experience meeting Dr. Greenup and staff was informative and impressive."



[Read More](#)

Understanding Kidney Cancer: New Treatment Advances and Genetic Implications

Sharon



Richard Edelson, MD



YaleNewHavenHealth
Smilow Cancer Hospital

Yale CANCER CENTER
A Comprehensive Cancer Center Designated
by the National Cancer Institute

Richard Edelson, MD, was presented with the **Yale Cancer Center Lifetime Achievement Award** by Marcus Bosenberg, MD, PhD. Dr. Edelson has served as Chair of the Department of Dermatology at Yale School of Medicine for 36 years; he is the longest serving Chair in Yale School of Medicine's history. From 2003-2008, Dr. Edelson also served as Director of Yale Cancer Center and was instrumental in our NCI CCSG renewal, and the initial planning and launch of the building campaign for Smilow Cancer Hospital. A leader in immunobiology, Dr. Edelson described and named Cutaneous T-Cell Lymphoma and later devised Extracorporeal Photochemotherapy, which became the first FDA-approved immunotherapy for any cancer. He is one of eight selected graduates of the NIH Physician Scientist Training Program whose investigative careers were featured in an eight-hour audiobook narrated by actor Alan Alda and released by Audible.com as a tribute to pivotal federally funded scientifically-driven medical advances.

Yale Cancer Center Award for Clinical Excellence



Nikolai Podoltsev, MD, PhD



Jennifer Moliterno, MD, FAANS

YaleNewHavenHealth
Smilow Cancer Hospital

Yale CANCER CENTER
A Comprehensive Cancer Center Designated
by the National Cancer Institute

The **Yale Cancer Center Awards for Excellence in Clinical Care** were presented by Kevin Billingsley, MD, MBA, FACS, to two outstanding physicians at Smilow Cancer Hospital: **Nikolai Podoltsev, MD, PhD**, Associate Professor of Medicine (Hematology), and **Jennifer Moliterno, MD, FAANS**, Associate Professor of Neurosurgery and Director of the Chênevert Family Brain Tumor Center at Smilow Cancer Hospital and Yale Cancer Center. Dr. Podoltsev was described as magnanimous, kind, and brilliant, and a 'triple threat' in medicine, who is not only a legendary educator with a depth of knowledge and willingness to share, but a clinician whose "real heart of his work lies with his dedication to his patients." Dr. Moliterno was recognized for her technical brilliance and dexterity and speed when operating, with a focus on optimal outcomes for her patients, while taking a

Smilow Shares

THURSDAY, MARCH 31 | 7:00PM

Understanding Kidney Cancer: New Treatment Advances Genetic Implications

[Read More](#)

Tune in to Yale Cancer Answers for a discussion with Dr. Ilana Richman on the importance of screening for breast and lung cancers, and new guidelines, in honor of National Cancer Prevention Month. Listen on Connecticut Public Radio or download our podcast from iTunes.



[Read More](#)

Congratulations to Pamela Kunz, MD, Director of the Center for Gastrointestinal Cancers at Smilow Cancer Hospital and Yale Cancer Center and Vice Chief of Diversity, Equity and Inclusion for Medical Oncology at Yale Cancer Center. Dr. Kunz has been named to the National Cancer Institute Equity Council EIP Subcommittee to help improve representation of women & under-represented groups in leadership positions in clinical trial enterprises.




operating, with a focus on special care for not patients, but talking a holistic, thoughtful, and compassionate approach to patient care. In addition, Dr. Moliterno was thanked for her dedicated support of Smilow Cancer Hospital through patient advocacy and fundraising.

Ruth McCorkle Oncology Advanced Practice Provider Award



Carol Staugaard, APRN-BC



YaleNewHavenHealth
Smilow Cancer Hospital


Yale CANCER CENTER
A Comprehensive Cancer Center Designated
by the National Cancer Institute

The **Ruth McCorkle Oncology Advanced Practice Provider Award** was presented by Kim Slusser, MSN, RN, CHPN, NEA-BC, Vice President for Patient Services at Smilow Cancer Hospital, and Vanna Dest, APRN, Senior Program Manager of the Oncology Advanced Practice Providers at Smilow Cancer Hospital. Vanna began by sharing reflections of Ruth, the “Godmother of Oncology Nursing,” who recognized the importance and contributions of APPs. Kim continued by announcing this year’s award winner, **Carol Staugaard, APRN-BC**. Carol has cared for patients at Yale New Haven Hospital since 1982 and has put our patients with gastrointestinal cancers and their loved ones at the forefront of her work since 2002, when she joined the GI medical oncology team. Her colleagues describe her as “compassionate, nurturing, stellar, calm, a voice of reason, and the unbreaking backbone of our team.”

Yale Cancer Center Award for Leadership in DEI



Faye Rogers, PhD



YaleNewHavenHealth
Smilow Cancer Hospital

Yale CANCER CENTER
A Comprehensive Cancer Center Designated
by the National Cancer Institute

Faye Rogers, PhD, was awarded the **Yale Cancer Center Award for Leadership in Diversity, Equity, and Inclusion**. Dr. Rogers is an Associate Professor of Therapeutic Radiology and is the Vice Chair for Diversity, Equity, and Inclusion. Since 2008, Dr. Rogers has been an active member of Yale Cancer Center and is a member of the Radiobiology and Radiotherapy



[Read More](#)

Dr. Michaela Dinan, Co-Leader of Yale Cancer Center's Cancer Prevention and Control Research Program, honors National Cancer Prevention Month. "Individuals should discuss what cancer screening is appropriate for them with their doctor. Colorectal, breast, prostate, and lung cancer screening can save lives."



[Read More](#)

Our clinical teams at Smilow Cancer Hospital and our Smilow Cancer Hospital Care Centers are proud to provide our patients with the latest in COVID therapies. Here's Marcus Rabovsky from our team at the Smilow Cancer Hospital Care Center in Orange preparing a therapy for one of his patients. Thank you, Marcus!



Research Program. During this time, she has distinguished herself through scientific accomplishments as well as her commitment to enhancing the culture both at Yale Cancer Center and in the basic sciences at Yale overall. She serves as Associate Director of the Yale MD-PhD Program and directs the Yale BioMed Amgen Scholars Program. In these roles she has had notable success supporting trainees from backgrounds traditionally underrepresented in biomedicine.

The **Yale Cancer Center Award for Mentorship Excellence** was presented to **Alfred Lee, MD, PhD**, Associate Professor of Medicine (Hematology) and Director of the Hematology/Oncology Fellowship Program, and the **Yale Cancer Center Award for Teaching Excellence** was presented to both **David F. Stern, MD, PhD**, Professor of Pathology and Associate Cancer Center Director for Shared Resources, and **Aarti Bhatia, MD, MPH**, Assistant Professor of Medicine (Medical Oncology).

The **Class of 1961 Cancer Research Awards** were presented to **Rong Fan, PhD**, Professor of Biomedical Engineering and of Pathology, and **Shangqin Guo, PhD**, Associate Professor in Cell Biology. They were honored for their significant accomplishments in cancer research as young members of the faculty, coupled with the expectation for future outstanding contributions to the causes of cancer and the development of novel cancer treatments.

The **Yale Cancer Center Population Science Research Prize** was presented to **Elizabeth Claus, PhD, MD**, Professor of Biostatistics. Dr. Claus was given her award for her work on the study “Environmental and sex-specific molecular signatures of glioma causation,” published in the *Journal of Neuro-Oncology*.

The **Yale Cancer Center Translational Science Research Prize** was presented to **Faye Rogers, PhD**, Associate Professor of Therapeutic Radiology, for her paper in *Nature Biotechnology*, “Direct targeting of amplified gene loci for proapoptotic anticancer therapy.”

The **Yale Cancer Center Clinical Science Research Prize** was awarded to **Lajos Pusztai, MD, DPhil**, Professor of Medicine (Medical Oncology), for his publication in *Cancer Cell* “Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial.”

The **Yale Cancer Center Basic Science Research Prizes** were presented to **Marcus Bosenberg, MD, PhD**, Professor of Pathology, Dermatology, and Immunology, Director of the Yale Center for Immuno-Oncology, and **Qin Yan, PhD**, Associate Professor of Pathology, for their publication in *Nature*, “KDM5B promotes immune evasion by recruiting SETDB1 to silence retroelements.”

Notables

The Yale School of Medicine **Office of Health Equity Research** has announced 25 finalists and 5 recipients of their **Excellence Award**, including several members of Yale Cancer Center. YCC members Kim Blenman, PhD, MS. Anup Sharma, PhD. Lajos Pusztai, MD, DPhil, and David Rimm, MD.



[Read More](#)

Dr. Maryam Lustberg, Director of the Center for Breast Cancer at Smilow Cancer Hospital and Yale Cancer Center and Chief of Breast Medical Oncology, recently sat down with Richard Paxman, CEO of Paxman Scalp Cooling, for his new podcast, Changing the Face of Cancer. They discussed the innovative cooling technology available at Smilow Cancer Hospital and several of our Care Centers that helps to combat and prevent chemotherapy-induced alopecia.



[Read More](#)

Barbara Burtness, MD, Associate Cancer Center Director for Diversity, Equity, and Inclusion at Yale Cancer Center, shares “Research to find ways to overcome these barriers, and the development of a cancer

workforce that represents all our communities, is of paramount



PhD, were among **award recipients** for their paper:

- Yaghoobi V, Moutafi M, Aung TN, Pelekanou V, Yaghoubi S, Blenman K, Ibrahim E, Vathiotis IA, Shafi S, Sharma A, O'Meara T, Fernandez AI, Puzstai L, Rimm DL. Quantitative assessment of the immune microenvironment in African American Triple Negative Breast Cancer: A case-control study. *Breast Cancer Res.* 2021 Dec 14;23(1):113.

YCC members Melinda Irwin, PhD, MPH, Charles Fuchs, MD, MPH, Cary Gross, MD, Farzana Pashankar, MD, MRCP, Beth Jones, PhD, MPH, and Asher Marks, MD, were selected as **award finalists** for their papers:

- Cheng E, Soulos PR, Irwin ML, Feliciano EM, Presley CJ, Fuchs CS, Meyerhardt JA, Gross CP. Neighborhood and individual socioeconomic disadvantage and survival among patients with nonmetastatic common cancers. *JAMA Network Open.* 2021 Dec 1;4(12):e2139593
- Puthenpura V, Canavan ME, Poynter JN, Roth M, Pashankar FD, Jones BA, Marks AM. Racial/ethnic, socioeconomic, and geographic survival disparities in adolescents and young adults with primary central nervous system tumors *Pediatric Blood & Cancer.* 2021 Jul;68(7):e28970.

Maryam Lustberg, MD, MPH, Associate Professor of Medicine (Medical Oncology) and Director of the Center for Breast Cancer at Smilow Cancer Hospital and Yale Cancer Center, has been named **co-editor** of the journal ***Cancer Medicine***.

Roy S. Herbst, MD, PhD, will present the Keynote Lecture at the 2022 **Targeted Therapies of Lung Cancer (TTL) Meeting** on Thursday, February 24 at 3:45pm on "22 Years of Progress in the Treatment of Non-Small Cell Lung Cancer: Targeted Therapy, Immunotherapy and the IASLC Santa Monica Meeting." Dr. Herbst will also be presented with an award at the meeting from the **International Association for the Study of Lung Cancer (IASLC)** in recognition of his dedication and service to IASLC and TTL.

Andrew Goodman, PhD, C.N.H. Long Professor of Microbial Pathogenesis, Director of Microbial Sciences Institute, and a member of Yale Cancer Center's Developmental Therapeutics Research Program, has been named a **Fellow of the American Academy of Microbiology**.

Smita Krishnaswamy, PhD, Associate Professor of Genetics and Computer Science, and a member of Yale Cancer Center's Cancer Immunology Research Program, was awarded the **National Science Foundation CAREER Award**, as well as a **Sloan Research Fellowship**.

Lauren A. Baldassarre, MD, FACC, FSCMR, Associate Professor of Medicine and Radiology & Biomedical Imaging and Director of Smilow Cancer Hospital's Cardio-Oncology Program, has been elected to the **Society for Cardiovascular Magnetic Resonance (SCMR) Board of Trustees**.

The **Paul G. Allen Frontiers Group** has named **Grace Chen, PhD**, Assistant Professor of Immunobiology, and **Joseph Craft, MD**, Paul B. Beeson Professor of Medicine and Professor of Immunobiology, as **Allen Distinguished Investigators**. Dr. Chen and Dr. Craft are both members of Yale Cancer Center's Cancer Immunology Research Program.

Please join us in welcoming **Jennifer Watkins, MS**, and **Latha Sudhakar**

medicine, but are also reminded of the work that remains. While new research advances cancer treatments, grave disparities in cancer outcomes result from barriers to accessing cancer care and research, and the co-morbidities result from marginalization.

Research to find ways to overcome these barriers, and the development of a cancer workforce that represents all our communities, is of paramount importance.

—Barbara Burtness, MD



YaleNewHavenHealth
Smilow Cancer Hospital

Yale
CANCER
CENTER
A Comprehensive Cancer Center Designated
by the National Cancer Institute

[Read More](#)

YaleNewHavenHealth
Smilow Cancer Hospital

Yale
CANCER
CENTER
A Comprehensive Cancer Center Designated
by the National Cancer Institute



[Read More](#)

"World Cancer Day gives us all a chance to pause and think about the role we play when it comes to closing the care gap in cancer," says Kim Slusser, RN, MSN, Vice President for Patient Services at Smilow Cancer Hospital.



World Cancer Day is a time for us to raise awareness of the work ahead—particularly in closing the gap in equitable care for everyone around the globe. We are still living where barriers to receiving fundamental preventative screening and cancer treatments exist for many. While we should acknowledge all that has been accomplished in cancer prevention, diagnosis, and treatment, we need to continue efforts and innovate ways to close the cancer care gap. We all have a role to play, whether it is research, education, or clinical care—we can all contribute to this vision.

KIM SLUSSER, RN, MSN

YaleNewHavenHealth
Smilow Cancer Hospital

Yale
CANCER
CENTER
A Comprehensive Cancer Center Designated
by the National Cancer Institute

[Read More](#)

Chief Medical Officer at Smilow Cancer Hospital, Kevin Billingsley, MD, MBA, acknowledges the challenges that still lie ahead in order to Close the Care Gap. "We must make cancer care accessible to all patients."



We are enormously fortunate to care for patients with cancer at a time when advances have made cure and long term disease management a reality for more individuals every day.

lease join us in welcoming Jennifer Watkins, MS, and Latha Sudhakar, MS, PMP, to Smilow Cancer Hospital as Directors of Operations and Planning. Ms. Watkins started on February 14 and supports the Center for Breast Cancer, the Chênevert Family Brain Tumor Center, and the Center for Gynecologic Cancers. She joins Smilow from the Department of Medicine, Division of Rheumatology at Penn Medicine where she served as Director of Division Administration and provided divisional leadership and strategic direction for faculty practice operations and divisional finances, ensuring the accomplishment of divisional goals and objectives.

As of February 28, Ms. Sudhakar will be working with the Center for Lymphomas, the Center for Leukemias, the Center for Myeloma, and the Center for Classical Hematology. She is currently a Senior Consultant in the Office of Strategy Management at YNH where she provides strategic insight and project management expertise to identify, address, and solve complex healthcare challenges across the Yale New Haven Health enterprise.

Kevin Vest, MBA, Vice President, Smilow Cancer Hospital, Yale New Haven Health, commented, "In these roles, Latha and Jennifer will partner with faculty and staff across the health system to advance the strategic priorities of the respective Centers, accelerate team science opportunities, and facilitate the delivery of our Signature of Care at sites across the health system, from Greenwich to Westerly."

In observance of **Dress in Blue Day** in honor of **colorectal cancer screening and awareness on Friday, March 4**, we invite you to gather your coworkers for a group photo and share it to post on Smilow Cancer Hospital's social media channels. A **downloadable sign** is available to include in your photos if you wish. Get creative and share lots of blue with us! Please send your photos to canceranswers@yale.edu by noon on Friday!

The **Genomics, Genetics, and Epigenetics Research Program** is proud to welcome **Anup Sharma, PhD**, a Research Scientist in the Department of Surgery. Dr. Sharma's current research focuses on understanding the complex interplay between the environment and genetic and epigenetic alterations in carcinogenesis and disease progression, and on exploiting this understanding in developing novel biomarkers for diagnosis and risk stratification as well as in identifying targets for therapeutic intervention. Dr. Sharma's primary focus is targeting inter tumor heterogeneity and understanding both genetic and epigenetic alterations for biomarker development and cancer therapy, and the development of genomic technologies for correlative and functional cancer research. In addition, he has worked to develop nanotechnology-based approaches for the detection of DNA methylation that has helped advance detection of methylation from liquid biopsy.

Diversity, Equity, and Inclusion

Black History Month

Black History Month provides an occasion to reflect on Black History in cancer medicine, both with respect to the state of cancer care for Black Americans, and the achievements and struggles of Black cancer physicians, scientists, and health care workers. An increased research focus on health



However, one of our most daunting challenges remains before us. To meet that challenge we must make cancer care increasingly accessible to all patients and provide care that aligns within the cultural context in which our patients live. By providing care that is responsive to the needs of all of our patients, we will be answering our highest calling as cancer care professionals."

KEVIN BILLINGSLEY, MD, MBA
#WorldCancerDay
#NothingWillStopUs




YaleNewHavenHealth
Smilow Cancer Hospital

Yale CANCER CENTER
A Comprehensive Cancer Center Designated
by the National Cancer Institute

Read More

On World Cancer Day, Eric P. Winer, MD, Director of Yale Cancer Center and Physician-in-Chief of Smilow Cancer Hospital, recognizes that the burden of cancer extends beyond our local community, throughout the country, and around the globe. Yale Cancer Center and Smilow Cancer Hospital will contribute to an innovative, global solution.



"Today, on World Cancer Day, we recognize the tremendous toll that cancer takes on our community, our country, and around the globe. I believe that Yale Cancer Center and Smilow Cancer Hospital can provide the best possible clinical care and look forward to continuing our efforts to conduct the most innovative and significant research in the coming years."

ERIC P. WINER, MD
Director, Yale Cancer Center
Physician-in-Chief,
Smilow Cancer Hospital
#WorldCancerDay
#NothingWillStopUs



YaleNewHavenHealth
Smilow Cancer Hospital

Yale CANCER CENTER
A Comprehensive Cancer Center Designated
by the National Cancer Institute

Read More

 Watch @DrEricWiner host @YaleCancer Grand Rounds on "A New Deal for Cancer" with CharlesFuchsMD @AbbeGluck @mirwin_yale @cpgYale and Greg Simon, covering 50 years since the [#NationalCancerAct](https://twitter.com/hashtag/NationalCancerAct)

 Join us at Noon today for Yale Cancer Center Grand Rounds. @DrEricWiner hosts a discussion on "A New Deal for Cancer" with @CharlesFuchsMD @AbbeGluck @mirwin_yale @cpgYale and Greg Simon.

 Exciting findings from new research led by @DanielPetrylak validate

disparities has documented the degree to which African American patients suffer from higher death rates and shorter survival for many common cancers. While the causes of these disparities are multiple, the most important drivers are centered in inequitable healthcare — poor access, biased care, and a failure to achieve the accepted standard of care. The contribution of systemic racism to the gross inequities in health care cannot be overemphasized. Interventions to improve access and to provide culturally sensitive outreach to patients and our communities can reduce disparities.

The field of oncology has always benefited from the contributions of Black physicians. Perhaps most famously, Jane Wright, MD, was one of the founders of the American Society of Clinical Oncology (ASCO). At a time when there were only a few hundred Black women physicians in the United States, she had a remarkable career in cancer medicine. In 1955, Dr. Wright became an Associate Professor of Surgical Research at New York University and Director of Cancer Chemotherapy Research at New York University Medical Center. President Lyndon Johnson appointed Dr. Wright to the President's Commission on Heart Disease, Cancer, and Stroke. Subsequently, she was named Professor of Surgery, Head of the Cancer Chemotherapy Department, and Associate Dean at New York Medical College, her alma mater. She was also the first woman President of the New York Cancer Society.

Today, 58 years following the founding of ASCO, only 3% of American oncologists are Black. To put this in perspective, 13.4% of the population is Black, and as noted, Black Americans bear a disproportionate burden of cancer death. Currently, about 6% of medical students and 6% of internal medicine residents are Black, and 3.9% of current oncology fellows are Black.

Our commitment at Yale Cancer Center and Smilow Cancer Hospital is to support the recruitment, mentorship, and success of Black trainees, cancer researchers, and physicians, to bend the arc of cancer history in the Black community.

Paid Child Rearing Leave Extended

We are pleased to announce that Yale School of Medicine has extended its paid child rearing leave for eligible faculty. Thanks to the support of Yale Cancer Center members including Valerie Horsley, PhD, Associate Professor of Molecular, Cellular, and Developmental Biology, Associate Professor of Dermatology, and a member of the Cancer Signaling Networks Research Program, and Megan King, PhD, Associate Professor of Cell Biology and of Molecular, Cellular, and Developmental Biology, Co-Leader of the Radiobiology and Radiotherapy Research Program, and Associate Cancer Center Director of Basic Science, leave has been extended from eight to 12 weeks.

Dr. King commented, "Valerie was instrumental in getting the family leave legislation passed at the state level that made this possible. The Connecticut Paid Family and Medical Leave Program will also provide parental leave benefits to anyone employed in the state, which will include trainees such as postdoctoral associates, so it is a win for all, not just our faculty!"

Barbara Burtness, MD, Interim Associate Cancer Center Director for Diversity, Equity, and Inclusion marked this as a monumental win for women in medicine and science. "This is such a wonderful breakthrough for women

novel effective therapy for aggressive muscle-invasive #bladdercancer. Data to be presented Friday at #ASCOGU22.



New research led by Dr. Alessandro Santin in @BrJCancer shows promising drug combination of ixabepilone + bevacizumab is effective in treating women with advanced #ovariancancer.



Dr. Cary Gross @cpgYALE @YaleCOPPER on #cancerpreventionmonth—"Screening such as #colonoscopy and #mammograms are widely available, and vaccines such as the #HPVvaccine are decreasing the incidence of #cervicalcancer."



Tune in tonight at 7:30pm to Yale Cancer Answers for a discussion with @llanaRichman on the importance of screening for #breastcancer and #lungcancer in honor of #NationalCancerPreventionMonth. Listen live on @wnpr or download our podcast from iTunes.



Happy International Day of Women and Girls in Science from @YaleCancer



New research led by @GeorgeGoshuaMD reveal cost-effectiveness of 2nd-line treatment strategies in chronic immune thrombocytopenia (ITP). Results fill gap identified in @ASH_Hematology guidelines.



Congratulations to @DrRoyHerbstYale named inaugural Deputy Director for Clinical Affairs @YaleCancer to support the integration of clinical, translational, and basic research programs.



Listen live today at noon and 4:25PM to hear @YaleCancer and @SmilowCancer members, including Drs. Meena Moran and @maryam_lustberg, speaking at the @NCCN 2022 #BreastCancer Congress.



We're pleased to announce new leadership appointments for Drs.

in medicine and science. This is such a wonderful breakthrough for women working in medicine and science in the state of Connecticut. I couldn't be prouder of the role my fellow YCC members, Drs. King and Horsley, played in bringing attention to the need for a humane child rearing leave policy."

You can view the updated policy at [this link](#).

Employee Profile: Michele Robertino

As the first person patients see when they arrive for their appointment on the 8th floor of Smilow Cancer Hospital, Michele Robertino takes her role seriously, but finds time to get to know patients as well and has both laughed and cried with them. She has known many of them since she started her position as a Clinical Front Desk Receptionist for Smilow Ambulatory Multispecialty Care on the eighth floor six years ago, and she has been with Smilow for 12 years. Michele handles all the tasks involved with check-in, as well as inventory, answering phones, and obtaining and distributing paperwork, but sees her overall goal as making a difference in someone's life.



As part of a high-volume clinic, there are typically between 200-300 appointment check-ins a day, of which Michele handles about 100, ranging from blood work to chemotherapy infusion appointments. Patients often have multiple appointments and doctor's visit scheduled for one day. "Patients come here knowing they are not going to have the best day," said Michele. "So, I always greet them with a smile and try to make them feel as comfortable and welcome as possible. Doing it every day, and then working at a catering business on the weekends, I don't often have a chance to stop and think about how my role affects their lives, but then you receive a note of thanks, you realize the impact you have had."

Maureen Major Campos, RN, MS, Director of Patient Services at Smilow

Cancer Hospital said, "Michele is often the 'early check-in' member of our NP8 team. She meets patients with a warm smile and a confidence that lets patients know that they are in the right place and will be well cared for. I value her assessment of how we are caring for our patients and know she will arc up concerns as she encounters them with a solution or just a basic question about how best to navigate. This became a true art during the pandemic, and I value all members of our team, including Michele!"

#OUTOFTHEBLUETHANKS to the Admin Team

Mark Lemmon @LemmonFerguson, Daniel DiMaio & Megan King @LuskingL to continue to build & support research at @YaleCancer.



Dr. Carlos Fernandez-Hernando on obesity-driven

#hepatocellularcarcinoma – "About 30% of the population has nonalcoholic fatty liver disease, which is caused by #obesity, a crisis seen in all Western societies."



Several members of our @YaleGICancers &

@YaleLiverCancer teams 'traveled' to share their insight at the UAE Egypt Saudi Arabia Hepatocellular Cancer Education Collaboration Conference today! Thank you



.@mleapman @Yale_Urology strives to improve screening, diagnosis, and management of early stage #prostatecancer. Watch his @YaleCancer Grand Rounds to hear about a new risk assessment tool.

Calendar

Endocrinology Clinical Dilemma

February 18; 12:00 PM

Shanzay Haider

[Learn More](#)

GYN Seminar

February 18; 12:00 PM

Non-gestational Trophoblastic Neoplasms: What Do We Know

Deyin Xing, MD, PhD

[Learn More](#)

Yale Cancer Answers

February 20; 7:30 PM

NPR

Kidney Cancer Awareness

David A. Braun, MD, PhD

[Learn More](#)


MB&B Seminar

February 21; 12:00 PM

The End of the Message: Molecular Insights into the mRNA poly(A) Tail Machinery

Lori Passmore

[Learn More](#)



Yale Cancer Center & Smilow Cancer Hospital's #OUTOFTHEBLUETHANKS recently recognized the following senior administrative assistants from the Yale Cancer Center administrative team: **Gina Cassesse, N'Kiyah Galberth, and Lucilina Gilkes**. Gina, N'Kiyah, and Luci were praised collectively by their managers for being true team players over the past few months during the recent Physician- Scientist Track (PST) Fellowship Interview season. What struck their managers most during this time was their willingness to help the team however they could. They worked together to make sure everything was covered when shifting priorities and other coverage needs posed unexpected hurdles throughout the process. No matter what they were asked to help with, they never once said they could not assist and adapted to every challenge that came their way. Not only have their managers been pleased with their performance during this particularly busy time, but the faculty they have been supporting have been equally impressed with their performance. Thank you, Gina, N'Kiyah, and Luci—your willingness to support your colleagues is admirable and appreciated!

Yale Cancer Center & Smilow Cancer Hospital's #OUTOFTHEBLUETHANKS program is a staff recognition initiative to show appreciation to employees who have exemplified an above-and-beyond effort or an outstanding contribution to the team. If you are interested in submitting a nomination, please complete this **nomination form** and return it to the Director's Office c/o Anna Raso.

Recent Publications

McGregor B, O'Donnell PH, Balar A, Petrylak D, Rosenberg J, Yu EY, Quinn DI, Heath EI, Campbell M, Hepp Z, McKay C, Steinberg J, Regnault A,

Mazerolle F, Galsky MD.

Health-related Quality of Life of Patients with Locally Advanced or Metastatic Urothelial Cancer Treated with Enfortumab Vedotin after Platinum and PD-1/PD-L1 Inhibitor Therapy: Results from Cohort 1 of the Phase 2 EV-201 Clinical Trial

European Urology, Online ahead of print.

[Read More](#)

Mezzanotte JN, Grimm M, Shinde NV, Nolan T, Worthen-Chaudhari L, Williams NO, Lustberg MB.

Updates in the Treatment of Chemotherapy-Induced Peripheral

Yale Cancer Center Grand Rounds

February 22; 12:00 PM

Dysregulated Transmembrane Ion Gradients Highlight Cancer Invasion And Proliferation and Over The River And Through The Woods And Into The Brain We Go: Lupus Autoantibodies Offer A New Pathway To Treating Brain Tumors

James E. Hansen, MD, MS and D.S.

Fahmeed Hyder, PhD

[Learn More](#)

Human and Translational Immunology Seminar Series

February 22; 4:00 PM

Lyosomes, Mitochondria, and the Endoplasmic Reticulum in Autoinflammatory T Cells

Cornelia Weyand, MD, PhD

[Learn More](#)

Neuroendocrine Conference

February 23; 4:00 PM

Board Review: Pituitary

Silvio Inzucchi, MD

[Learn More](#)

Therapeutic Radiology Grand Rounds

February 24; 9:00 AM

Magnetic Resonance Guided Radiation Therapy (MRgRT) with an MR-Lina

Chandrasekhar Kota

[Learn More](#)

Pharmacology Seminar Series

February 24; 12:30 PM

Dr. Michael Eck

[Learn More](#)

Pathology Grand Rounds

February 24; 12:30 PM

How NMR Can Assist Us in Understanding Disease

Stephen Meredith, MD

[Learn More](#)

Cancer Genetics and Prevention Seminar

February 24; 2:30 PM

[Learn More](#)

Interactive Workshop

February 24; 4:00 PM

Can I Grow through Difficult Experiences, Like This Pandemic?

Kristine Olson, MD and Kendall Palladino

Neuropathy

Current Treatment Options in Oncology, Online ahead of print.

Read More

Boni V, Fidler MJ, Arkenau HT, Spira A, Meric-Bernstam F, Uboha N, Sanborn RE, Sweis RF, LoRusso P, Nagasaka M, Garcia-Corbacho J, Jalal S, Harding JJ, Kim SK, Miedema IHC, Vugts DJ, Huisman MC, Zwezerijnen GJC, van Dongen GAMS, Menke-van der Houven van Oordt CW, Wang S, Dang T, Zein IA, Vasiljeva O, Lyman SK, Paton V, Hannah A, Liu JF.

Praluzatamab Ravtansine, A CD166-Targeting Antibody-Drug Conjugate, In Patients With Advanced Solid Tumors: An Open-Label Phase 1/2 Trial

Clinical Cancer Research, Online ahead of print.

Read More

Reader JC, Fan C, Ory EC, Ju J, Lee R, Vitolo MI, Smith P, Wu S, Ching MMN, Asiedu EB, Jewell CM, Rao GG, Fulton A, Webb TJ, Yang P, Santin AD, Huang HC, Martin SS, Roque DM.

Microtentacle Formation in Ovarian Carcinoma

Cancers, 14(3):800.

Read More

Cao A, Ferrucci LM, Caan BJ, Irwin ML.

Effect of Exercise on Sarcopenia among Cancer Survivors: A Systematic Review

Cancers, 14(3):786.

Read More

Gupta A, Afinogenova Y, Podoltsev NA, Danve A.

Concurrent Use Of Tumor Necrosis Factor Inhibitor And Tyrosine Kinase Inhibitor In Ankylosing Spondylitis And Myeloid Neoplasm

European Journal of Rheumatology, Online ahead of print.

Read More

Roque DM, Siegel ER, Buza N, Bellone S, Silasi DA, Huang GS, Andikyan V, Clark M, Azodi M, Schwartz PE, Rao GG, Reader JC, Hui P, Tymon-Rosario JR, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Santin AD.

Randomised Phase II Trial Of Weekly Ixabepilone ± Biweekly Bevacizumab For Platinum-Resistant Or Refractory Ovarian/Fallopian Tube/Primary Peritoneal Cancer

British Journal of Cancer, Online ahead of print.

Read More

Deng Y, Bartosovic M, Kukanja P, Zhang D, Liu Y, Su G, Enniful A, Bai Z, Castelo-Branco G, Fan R.

Spatial-CUT&Tag: Spatially Resolved Chromatin Modification Profiling At The Cellular Level

Science, 375(6581):681-686.

Read More

Yun S, Greco V.

From Start To Finish-A Molecular Link In Wound Repair

Science, 375(6581):619-620.

Read More

Learn More

Yale Liver Diamond Jubilee

February 25; 8:30 AM

Celebrating 75 Years of Academic Hepatology at Yale

Nancy J. Brown, MD | Gary Desir, MD | Michael Nathanson, MD, PhD | Mario Strazzabosco, MD, PhD | James Boyer, MD, FACEP | Guadalupe Garcia-Tsao, MD, FRCP | Clifford Bogue, MD | Chen Liu, MD, PhD | Noah Palm, PhD | Pramod Mistry, MBBS, PhD, MA, MD | Tamar Taddei, MD | David Mulligan, MD, FACS, FAST, FAASLD | David C. Madoff, MD | Michael Caplan, PhD, MD | Rob Goodman, MBBCh, MBA, BMSc | Jeffrey Weinreb, MD, FACR, FISMRM, FSABI | Gerald I Shulman, MD, PhD, MACP, MACE, FRCP | Dean Yimlamai, MD/PhD | Julius Chapiro, MD | Joseph Lim, MD | David N. Assis, MD | Jay H. Hoofnagle, MD | Scott Freidman, MD | Massimo Colombo, MD | Noah Terrault, MD, MPH | Michael Trauner, MD | Domenico Alvaro, MD | Ulrich Beuers | Jaime Bosch, MD, PhD | Luca Fabris, MD, PhD | Christina Ripoll, MD | Shiv Sarin, MD | Fatima Leite

Learn More

Endocrinology Clinical Dilemma

February 25; 12:00 PM

Priyadarshini Balasubramaniam

Learn More

Yale ASH 2021 Highlights

February 25; 12:00 PM

Multiple Myeloma

Natalia Neparidze, MD | Elan Gorshein, DO, JD, MPH | Terri Parker, MD | Noffar Bar, MD | Sabrina Browning, MD

Learn More

Yale Cancer Answers

February 27; 7:30 PM

NPR

Access to Ambulatory Care for Vulnerable Populations

Joseph Ross, MD, MHS

Learn More

NCCN Patient Webinar

February 28; 12:15 PM

Kidney Cancer

Brandon Manley MD | Sarah Hart, BSN, RN | Bryan Lewis

Gettinger S, Redman MW, Herbst RS.

Nivolumab Plus Ipilimumab for Previously Treated Stage IV Squamous Cell Lung Cancer-Reply

JAMA Oncology, Online ahead of print.

[Read More](#)

Hu C, Leche CA 2nd, Kiyatkin A, Yu Z, Stayrook SE, Ferguson KM, Lemmon MA.

Glioblastoma Mutations Alter EGFR Dimer Structure To Prevent Ligand Bias

Nature, Online ahead of print.

[Read More](#)

Schmid P, Cortes J, Dent R, Puztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Untch M, Fasching PA, Cardoso F, Andersen J, Patt D, Danso M, Ferreira M, Mouret-Reynier MA, Im SA, Ahn JH, Gion M, Baron-Hay S, Boileau JF, Ding Y, Tryfonidis K, Aktan G, Karantza V, O'Shaughnessy J; KEYNOTE-522 Investigators.

Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer

New England Journal of Medicine, 386(6):556-567

[Read More](#)

Simon B, Lou HJ, Huet-Calderwood C, Shi G, Boggon TJ, Turk BE, Calderwood DA.

Tousled-like Kinase 2 Targets ASF1 Histone Chaperones Through Client Mimicry

Nature Communications, 13(1):749

[Read More](#)

Goksu SY, Ozer M, Goksu BB, Wang R, Khatib J, Patel PA, Vusirikala M, Cole S, Seyhanli A, Collins RH, Chung S, Zeidan AM, Madanat YF.

The Impact Of Race And Ethnicity On Outcomes Of Patients With Myelodysplastic Syndromes: A Population-Based Analysis

Leukemia & Lymphoma, Online ahead of print.

[Read More](#)

Le Blanc J, Golshan M, Lannin D, Greenup R, Berger ER, Saridakis A, Horowitz N, Zanieski G, Avraham T, Mastroianni M, Park T.

Association of Medicaid Expansion with Post-mastectomy Reconstruction Rates

Annals of Surgical Oncology, Online ahead of print.

[Read More](#)

Kaye DR, Wilson LE, Greiner MA, Spees LP, Pritchard JE, Zhang T, Pollack CE, George D, Scales CD Jr, Baggett CD, Gross CP, Leapman MS, Wheeler SB, Dinan MA.

Patient, Provider, And Hospital Factors Associated With Oral Anti-Neoplastic Agent Initiation And Adherence In Older Patients With Metastatic Renal Cell Carcinoma

Journal of Geriatric Oncology, Online ahead of print.

[Read More](#)

Dieli-Conwright CM, Nelson RA, Simon MS, Irwin ML, Neuhaus ML, Reding

[Learn More](#)

Yale Cancer Center Grand Rounds/Schnog Lecture

March 1; 12:00 PM

Cathy Eng, MD, FACP, FASCO

[Learn More](#)

Yale Center for Immuno-Oncology Seminar (presented as part of the Human and Translational Immunology Program Seminar Series)

March 1; 4:00 PM

Andy J. Minn, MD, PhD

Yale Liver Center Seminar

March 1; 5:00 PM

Leveraging Energy Expenditure in the Management of Non-alcoholic Fatty Liver

David E. Cohen, MD, PhD

[Learn More](#)

Pathology Grand Rounds

March 3; 12:30 PM

Towards predictive biomarkers in early-stage HR2 positive breast cancer

Christina Curtis, PhD, MSc

[Learn More](#)

Cancer Genetics and Prevention Seminar

March 3; 2:30 PM

[Learn More](#)

Center for GI Cancers Weekly Seminar

March 3; 4:15 PM

Lisa Bodei, MD, PhD

[Learn More](#)

Smilow Cancer Hospital and Yale Cancer Center Clinical and Research Town Hall

March 3; 5:00 PM

[Learn More](#)

Share your news!

Please submit your recent publications, awards, and grant announcements to:

[Renee Gaudette](#)

Director, Public Affairs and Communications

KW, Crane TE, Manson JE, Nassir R, Shadyab AH, LaMonte M, Qi L, Thomson CA, Kroenke CH, Pan K, Chlebowski RT, Mortimer J.

Cardiometabolic Risk Factors, Physical Activity, And Postmenopausal Breast Cancer Mortality: Results From The Women's Health Initiative

BMC Women's Health, 22(1):32.

[Read More](#)

Patel K, Shergill S, Vadivelu N, Rajput K.

Analgesia for Gynecologic Oncologic Surgeries: A Narrative Review

Current Pain and Headache Reports, Online ahead of print.

[Read More](#)

Foldi J, Silber A, Reisenbichler E, Singh K, Fischbach N, Persico J, Adelson K, Katoch A, Horowitz N, Lannin D, Chagpar A, Park T, Marczyk M, Frederick C, Burrello T, Ibrahim E, Qing T, Bai Y, Blenman K, Rimm DL, Puzstai L.

Author Correction: Neoadjuvant Durvalumab Plus Weekly Nab-Paclitaxel And Dose-Dense Doxorubicin/Cyclophosphamide In Triple-Negative Breast Cancer

NPJ Breast Cancer, 8(1):17

[Read More](#)

Fernandez AI, Liu M, Bellizzi A, Brock J, Fadare O, Hanley K, Harigopal M, Jorns JM, Kuba MG, Ly A, Podoll M, Rabe K, Sanders MA, Singh K, Snir OL, Soong TR, Wei S, Wen H, Wong S, Yoon E, Puzstai L, Reisenbichler E, Rimm DL.

Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue

JAMA Oncology, Online ahead of print.

[Read More](#)

Makker V, Colombo N, Casado Herráez A, Santin AD, Colomba E, Miller DS, Fujiwara K, Pignata S, Baron-Hay S, Ray-Coquard I, Shapira-Frommer R, Ushijima K, Sakata J, Yonemori K, Kim YM, Guerra EM, Sanli UA, McCormack MM, Smith AD, Keefe S, Bird S, Dutta L, Orłowski RJ, Lorusso

D; Study 309–KEYNOTE-775 Investigators.

Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer

New England Journal of Medicine, 386(5):437-448.

[Read More](#)

Kibel AS, Inman BA, Pachynski RK, Vu T, Sheikh NA, Petrylak DP.

Videos of Sipuleucel-T Programmed T Cells Lysing Cells That Express Prostate Cancer Target Antigens

Journal of the National Cancer Institute, 114(2):310-313.

[Read More](#)

Sethi T, Montanari F, Foss F.

Safety Considerations With The Current Treatments For Peripheral T-Cell Lymphoma

Expert Opinion on Drug Safety, Online ahead of print.

[Read More](#)

Gross C.

Cancer 'Moonshot' Has Lofty New Goal: Halve Deaths In 25 Years

Nature.

[Read More](#)

Ngwube A, Franay C, Shah N

Post-transplant CD34+ Selected Stem Cell Boost As An Intervention For Declining Mixed Chimerism Following Reduced Intensity Conditioning Allogeneic Stem Cell Transplant In Children And Young Adults With Sickle Cell Disease: A Case Series

Pediatric Hematology and Oncology, Online ahead of print.

[Read More](#)

Funding and Award Opportunities

Yale Liver Center Pilot Grants

Funded through their NIH/NIDDK P30 Liver Center grant, these grants are to fund new liver-related research that should lead to future R01-type funding or other support.

Application Deadline: February 25, 2022

[Read More](#)

AACR Clinical Oncology Research (CORE) Training Fellowships

This program is designed to provide an effective industry-academic clinical practicum with a unique training opportunity to develop academic clinicians in drug development. Each fellowship provides \$100,000 over one year for the fellow to work on site at the facility of one of the AACR's pharmaceutical industry partners.

Application Deadline: February 28, 2022

[Read More](#)

International Lung Cancer Foundation Research Grants

Adequate research funding is key to furthering developments in lung cancer treatment. Through partnering with foundations, non-profits, corporations and individual donors, the International Lung Cancer Foundation (ILCF) provides multiple funding opportunities each year to facilitate scientific advances and save lives. Before beginning your application, please review each section of this website to learn more about our available grants and our process.

Application Deadline: February 28, 2022

[Read More](#)

Early K99/R00 Funding Opportunity Announcements

The NCI just reissued "early K99/R00" - NCI Pathway to Independence

Award for Outstanding Early-Stage Postdoctoral Researchers FOAs that might be of interest to some postdoctoral fellows.

- NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Not Allowed)
- NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Required)
- NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 - Independent Basic Experimental Studies with Humans Required)

Application Deadlines: February 28, 2022

[Read More](#)

NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00)

The purpose of this award is to increase and maintain a strong cohort of new

The purpose of this award is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions.

Application Deadline: February 28, 2022

Read More

NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 - Independent Basic Experimental Studies with Humans Required)

This FOA is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind.

Application Deadline: February 28, 2022

Read More

JH Milestone Fund 2022

This award is to support early-stage investigators and innovative research that improves understanding of bleeding, thrombosis or thrombolysis. The research can focus on the genetics, biochemistry or cell biology of coagulation or thrombolysis or on the causes, pathogenesis, diagnosis or treatment of bleeding and clotting disorders. In the absence of preliminary data, appropriate mentors and/or collaborators are important.

Letter of Intent Due: March 1, 2022

Further information: contact Richard.Carr@yale.edu

Ben and Catherine Ivy Foundation Emerging Leader Grant Award

Provides grant support to early-to-mid-career investigators conducting high-impact, high-reward translational research for glioblastoma. This award is intended to support ambitious pilot projects designed to identify drug

strategies appropriate for early-phase pharmacodynamic- and pharmacokinetic-driven clinical trials in partnership with the Ivy Brain Tumor Center.

Application Deadline: March 1, 2022

Read More

Ben and Catherine Ivy Foundation Translational Adult Glioma Grant Award

Provides grant support to investigators conducting high-impact, high-reward translational research for glioblastoma. This award is intended to support projects designed to contribute to identifying therapies that will impact the survival of patients with brain cancer.

Application Deadline: March 1, 2022

Read More

American Cancer Society - Institutional Research Grant Pilot Awards for

Underrepresented Minorities

The ACS will be supporting an additional pilot grant for an Assistant Professor who identifies as underrepresented in health-related sciences. The purpose of this grant is to provide seed money for the initiation of promising new projects or novel ideas by URM Yale Assistant Professors so that they can obtain preliminary results to enable them to compete successfully for national cancer research grants.

Letter of Intent Due: March 1, 2022

[Read More](#)

DeLuca Career Development Award 2022

The purpose of this career development award is to provide early career clinical or laboratory-based investigators in Hematology, the opportunity to focus on research to advance patient care, therapies, and outcomes and with the ultimate goal to achieve independent support for their research from a national agency. For further information contact Richard.Carr@yale.edu

Letter of Intent Due: March 1, 2022

[Read More](#)

The Mark Foundation Endeavor Awards

These awards support collaborative research projects that bring together investigators with diverse areas of expertise to tackle challenges in the prevention, diagnosis, and treatment of cancer. These grants are awarded to teams of three or more investigators to generate and integrate data from diverse lines of research and transform those insights into advances for cancer patients that could not be achieved by individual efforts.

Letter of Intent Due: March 1, 2022

[Read More](#)

The Society for Immunotherapy of Cancer (SITC) Women in Cancer Immunotherapy Network (WIN) Leadership Institute

SITC will be offering an in-person this summer on Aug. 1–2, 2022 in Seattle, WA. The program, championed by SITC Past President Lisa H. Butterfield, PhD, the society's first female president, is a professional development and networking event that seeks to empower emerging female leaders in the cancer immunotherapy field.

This program will feature presentations from experienced female leaders, panel discussions allowing participants to ask questions and interact with these leaders and our distinguished program organizers, and in-person networking opportunities.

Application Deadline: March 2, 2022

[Read More](#)

Breast Cancer Alliance: Exceptional Project Grants

BCA invites clinical doctors and research scientists, including post docs, at any stage of their careers whose primary focus is breast cancer to apply for an Exceptional Project Grant. This award recognizes creative, unique, and innovative research and is open to applicants at institutions throughout the contiguous United States. Only two nominees may be put forward by YCC.

Internal Deadline: March 6, 2022

[Read More](#)

BMSF Diversity in Clinical Trials Career Development Program

The intent of this program is to increase diversity in clinical trials. The initiative is comprised of a Career Development Program for early-stage

clinical investigators and a Clinical Investigator Pipeline Program (BMSF CIPP) for rising second-year medical students.

Application Deadline: March 15, 2022

Read More

Damon Runyon Cancer Research Foundation Fellowship Award

The Foundation encourages all theoretical and experimental research relevant to the study of cancer and the search for cancer causes, mechanisms, therapies and prevention.

Application Deadline: March 15, 2022

Read More

Sontag Foundation Distinguished Scientist Award

Recipients of the award are inspired individuals with projects that show potential to generate new knowledge relating to causes, cure or treatment of primary brain tumors/brain cancer.

Application Deadline: March 16, 2022

Read More

Data, Evaluation and Coordinating Center for: A Multilevel Approach to Connecting Underrepresented Populations to Clinical Trials (CUSP2CT) (U24)

The purpose of this FOA is to solicit applications for CUSP2CT U24 Data, Evaluation and Coordinating Center (DECC). The DECC is intended to support CUSP2CT, a program designed to increase referral to NCI-supported clinical trials among underrepresented racial/ethnic minority populations who experience disproportionately higher rates of incidence, morbidity, and mortality for numerous cancer types in comparison to Non-Hispanic Whites.

Application Deadline: March 28, 2022

Read More

U.S. and Low- and Middle-Income Country (LMIC) HIV-Associated Malignancy Research Centers

The purpose of this FOA is to support research on human immunodeficiency virus (HIV)-associated cancers in low- and middle-income countries (LMICs) through the formation of collaborative partnerships between investigators in the United States and investigators in LMICs.

Application Deadline: March 30, 2022

Read More

SITC FELLOWSHIPS for Early Career Scientists

SITC is dedicated to assisting investigators in advancing the science of immunotherapy and developing new therapeutic approaches. To further this goal, we are offering eight Fellowships and Technology Awards, totaling \$680,000 in funding. These Fellowships and Technology Awards are only available to SITC members.

- **Bristol Myers Squibb Postdoctoral Cancer Immunotherapy Translational Fellowship**
- **Amgen Cancer Immunotherapy in Hematologic Malignancies Fellowship**
- **AstraZeneca Immunotherapy in Lung Cancer Clinical Fellowship**
- **Merck Cancer Immunotherapy Clinical Fellowship**
- **Genentech Women in Cancer Immunotherapy Fellowship**
- **Nektar Therapeutics Equity and Inclusion in Cancer Immunotherapy Fellowship**
- **Mallinckrodt Pharmaceuticals Adverse Events in**

- **Mallinckrodt Pharmaceuticals Adverse Events in Cancer Immunotherapy Clinical Fellowship**
- **Natera ctDNA Immunotherapy Response Monitoring Fellowship and Technology Award**

Application Deadline: April 5, 2022

Read More

MRA Dermatology Fellowship & Junior Faculty Awards

The aim of this program is to drive greater interest and focus on melanoma in clinical practice and research related to the prevention, detection, diagnosis, and staging of melanoma.

- **MRA Dermatology Fellows Award (1 Year, \$35,000):** Supports dermatology residents, fellows, or post-docs in a dermatology program with research, demonstration, and/or pilot programs focused on melanoma prevention or improving early detection, diagnosis, or prognosis.
- **MRA Dermatology Junior Faculty/Clinical Instructor Award (Up to 2 Years, \$50,000 per year):** Supports new dermatology faculty (clinical instructors or new assistant professors) working in research on melanoma prevention or improving early detection, diagnosis, or prognosis.

Application Deadlines: April 20, 2022

Read More

Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61)

The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses.

Application Deadline: April 22, 2022

Read More

Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33)

This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still require further development and rigorous validation to encourage adoption by the research community.

Application Deadline: April 22, 2022

Read More

Yale Center for Gastrointestinal Cancers (CGIC) Seed Grant Program

This intramural seed grant program is designed to provide pilot funding for team-based basic, translational, clinical, or population health research projects focused on GI cancers.

Application Deadline: May 1, 2022

Read More

Pew-Stewart Scholars for Cancer Research

The Pew-Stewart Scholars for Cancer Research supports assistant professors of outstanding promise in science relevant to the advancement of a cure for cancer. The award provides \$300,000 in flexible support—\$75,000 per year for a four-year period.

Institutional Nomination Due: May 18, 2022

Read More

Epidemiologic Research on Emerging Risk Factors and Liver Cancer

Susceptibility (R01 and R21)

The purpose of these FOAs is to promote epidemiologic research investigating novel and innovative hypotheses on emerging risk factors (biological, environmental, and social) and their interplay with established risk factors (e.g., viral hepatitis) associated with the development of liver cancer (hepatocellular carcinoma and other histological subtypes) in the United States.

Application Deadline: June 16, 2022

Read More

Lasker Clinical Research Scholars Program (Si2/R00)

This program offers the opportunity for a unique bridge between the NIH intramural and extramural research communities and contains two phases. In the first phase, Lasker Scholars will receive appointments for up to 5-7 years as tenure-track investigators within the NIH Intramural Research Program with independent research budgets. In the second phase, successful scholars will receive up to 3 years of NIH support for their research at an extramural research facility; or, the Scholar can be considered to remain as an investigator within the intramural program.

Application Deadline: June 24, 2022

Read More

Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (R01)

This FOA will support the development and characterization of state-of-the-art biomimetic tissue-engineered technologies for cancer research.

Application Deadline: July 5, 2022

Read More